Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Incomplete Revascularization in the Long Term

Original Title: Long-Term Outcome of Incomplete Revascularization after Percutaneous Coronary Intervention in SCAAR (Swedish Coronary Angiography and Angioplasty Registry). Reference: Kristina Hambraeus et al. J Am Coll Cardiol Intv. 2016;9(3):207-215.

 

The aim of this study was to describe the evolution of patients with multivessel disease undergoing PCI with incomplete revascularization, and its probable association to death, repeat revascularization and MI in the long term.

Between 2006 and 2010 23342 patients with multivessel disease were identified in the SCAAR registry (Swedish Coronary Angiography and Angioplasty Registry). Incomplete revascularization was defined as any vessel with a lesion larger than 60% irrigating at least 10% of the myocardium.

Patients with incomplete revascularization (n = 15,165) were older, with more extensive coronary disease and often had STEMI at presentation, compared to those with complete revascularization (n = 8,177).

At one year, all cause mortality, AMI and repeat revascularization rates were higher among the incomplete revascularization patients, compared to those with complete revascularization (7.1% vs 3.8%, 10.4% vs 6.0% and 20.5% vs 8.5%, respectively).

After propensity score matching, the adjusted risk at one year for the composite of death, MI or revascularization was significantly higher for the incomplete revascularization group. (HR 2.12 CI 95% 1.98 to 2.28; p < 0.0001).

The adjusted risk of death and the combination of death/MI also resulted higher for the incomplete revascularization group with 1.29 (CI 95% 1.12 to 1.49; p=0.0005) and 1.42 (CI 95% 1.30 to 1.56; p<0.0001), respectively.

Conclusion
Incomplete revascularization at discharge in patients with multivessel disease undergoing PCI is associated with a high risk of adverse cardiac events at one year.

Editorial Comment
So far, the evidence is conflictive and generally indirect. Even though this study provides important data, is limited by its retrospective character and by the fact that it was carried out in different populations, which required several adjustments for researchers to be able to compare. Clearly, in almost all studies, patients with incomplete revascularization are always at higher risk, and their treatment was determined by the impossibility to receive a complete revascularization, rather than by choice.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...